| Trial ID: | L0487 |
| Source ID: | NCT05325099
|
| Associated Drug: |
Azacitidine
|
| Title: |
Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum
|
| Acronym: |
|
| Status: |
RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Acute Kidney Disease
|
| Interventions: |
DRUG: Azacitidine|DRUG: Placebo
|
| Outcome Measures: |
Primary: Renal composite outcome, 1. A decline of at least 50% in the estimated GFR (compared with baseline eGFR) 2. An increase of UPCR over 1000 mg/g 3. The onset of end-stage kidney disease, 2 years after recruitment | Secondary: Overall mortality and cardiovascular death, 2 years after recruitment
|
| Sponsor/Collaborators: |
Sponsor: National Taiwan University Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1|PHASE2
|
| Enrollment: |
60
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2024-04-18
|
| Completion Date: |
2026-05-31
|
| Results First Posted: |
|
| Last Update Posted: |
2025-02-20
|
| Locations: |
Yu Hsiang Chou, Taipei City, 116, Taiwan
|
| URL: |
https://clinicaltrials.gov/show/NCT05325099
|
